Brain Serotonin Transporter Occupancy by Oral Sibutramine Dosed to Steady State: A PET Study Using 11C-DASB in Healthy Humans
Peter S. Talbot(Queen's University Belfast), Julian C. Matthews(Manchester Academic Health Science Centre)
Cited by 28
Related Papers
A Multi-Center Randomized Proof-of-Concept Clinical Trial Applying [18F]FDG-PET for Evaluation of Metabolic Therapy with Rosiglitazone XR in Mild to Moderate Alzheimer's Disease
|Journal of Alzheimer s Disease|2011|109
A Comparison of Gray Matter Density in Restless Legs Syndrome Patients and Matched Controls Using Voxel‐Based Morphometry
|Journal of Neuroimaging|2010|44
IC‐P‐088: Effects of 12 months of treatment with the PPAR<i>γ</i> agonist rosiglitazone on brain glucose metabolism in Alzheimer's disease: A <sup>18</sup>F‐FDG PET study
|Alzheimer s & Dementia|2009|7
P1‐112: Effects of 12 months of treatment with the PPARγ agonist rosiglitazone on brain glucose metabolism in Alzheimer's Disease: A <sup>18</sup>F‐FDG PET study
|Alzheimer s & Dementia|2009|3
Validation and Pilot Application of [
|Advances in Alzheimer's disease|2011|0